Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial (Q38666574)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

13

0 references

author name string

Jin-Ji Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Caicun Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Yisheng Huang

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Jifeng Feng

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sun Lu

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Yong Song

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Cheng Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Gang Wu

8

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Li Zhang

9

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Ying Cheng

10

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Chengping Hu

11

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Gongyan Chen

12

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Xiaoqing Liu

14

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Hong Hong Yan

15

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Fen Lai Tan

16

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Wenzhao Zhong

17

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Yi-Long Wu

18

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

19 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

707-716

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Distribution of distant metastases from newly diagnosed non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic sites and survival in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy and chemotherapy of brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-o

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930262-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(17)30262-X

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38666574&oldid=2284892913"